Viracta Therapeutics Inc (VIRX)

$0.59

-0.04

(-5.63%)

Market is closed - opens 7 PM, 25 Jun 2024

Insights on Viracta Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 78.5% return, outperforming this stock by 138.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.4% return, outperforming this stock by 339.9%

Performance

  • $0.57
    $0.62
    $0.59
    downward going graph

    4.2%

    Downside

    Day's Volatility :8.79%

    Upside

    4.79%

    downward going graph
  • $0.43
    $1.68
    $0.59
    downward going graph

    27.12%

    Downside

    52 Weeks Volatility :74.4%

    Upside

    64.88%

    downward going graph

Returns

PeriodViracta Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-41.02%
0.9%
0.0%
6 Months
15.99%
8.7%
0.0%
1 Year
-55.66%
11.2%
0.0%
3 Years
-94.46%
17.3%
-24.2%

Highlights

Market Capitalization
23.6M
Book Value
$0.14
Earnings Per Share (EPS)
-1.23
Wall Street Target Price
5.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-51.49%
Return On Equity TTM
-154.33%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-51.9M
Diluted Eps TTM
-1.23
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.15
EPS Estimate Next Year
-0.98
EPS Estimate Current Quarter
-0.35
EPS Estimate Next Quarter
-0.31

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Viracta Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 747.46%

Current $0.59
Target $5.00

Technicals Summary

Sell

Neutral

Buy

Viracta Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Viracta Therapeutics Inc
Viracta Therapeutics Inc
-14.94%
15.99%
-55.66%
-94.46%
-96.02%
Moderna, Inc.
Moderna, Inc.
-19.93%
37.06%
10.79%
-39.4%
850.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
6.92%
23.97%
34.26%
93.43%
236.95%
Novo Nordisk A/s
Novo Nordisk A/s
4.35%
38.25%
80.59%
245.4%
453.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.57%
14.98%
34.9%
144.2%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Viracta Therapeutics Inc
Viracta Therapeutics Inc
1.23
NA
NA
-1.15
-1.54
-0.51
NA
0.14
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.7
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.93
30.93
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.78
49.78
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.61
30.61
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Viracta Therapeutics Inc
Viracta Therapeutics Inc
Buy
$23.6M
-96.02%
1.23
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.5B
850.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.3B
236.95%
30.93
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$644.0B
453.56%
49.78
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.7B
158.93%
30.61
39.46%

Institutional Holdings

  • Bvf Inc

    9.20%
  • Vanguard Group Inc

    2.96%
  • Samsara BioCapital, LLC

    1.76%
  • LAURION CAPITAL MANAGEMENT LP

    1.07%
  • Mccormack Advisors International

    0.93%
  • BlackRock Inc

    0.77%

Company Information

viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus, and will pursue opportunities to address other serious virus-associated disease.

Organization
Viracta Therapeutics Inc
Employees
40
CEO
Mr. Mark Andrew Rothera
Industry
Healthcare

FAQs